(Reuters) – s of OncoMed Pharmaceuticals Inc more than doubled on Tuesday after the biotechnology company said Celgene Corp would help it develop and market six of its experimental anti-cancer stem cell drugs. OncoMed will get upfront payments of $177.25 million, including $22.25…
Source:OncoMed stock doubles after cancer drug deal with Celgene
Tuesday, December 3, 2013
OncoMed stock doubles after cancer drug deal with Celgene
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment